Menu Search
Equities

Hansa Biopharma AB

HNSA:STO

Hansa Biopharma AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)40.66
  • Today's Change-0.40 / -0.97%
  • Shares traded102.19k
  • 1 Year change+12.07%
  • Beta1.3805
Data delayed at least 15 minutes, as of Sep 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 5 analysts offering 12 month price targets for Hansa Biopharma AB have a median target of 90.00, with a high estimate of 175.00 and a low estimate of 16.00. The median estimate represents a 121.35% increase from the last price of 40.66.
High330.4%175.00
Med121.3%90.00
Low-60.6%16.00

Earnings history & estimates in SEK

On Jul 18, 2024, Hansa Biopharma AB reported 2nd quarter 2024 losses of -3.30 per share.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate-1.13%
Hansa Biopharma AB reported annual 2023 losses of -15.83 per share on Jan 06, 2024.
Average growth rate-15.29%
More ▼

Revenue history & estimates in SEK

Hansa Biopharma AB (publ) had 2nd quarter 2024 revenues of 34.33m. This missed the 54.27m consensus estimate of the 4 analysts following the company. This was 41.91% above the prior year's 2nd quarter results.
Average growth rate+13.86%
Hansa Biopharma AB (publ) had revenues for the full year 2023 of 134.09m. This was 13.22% below the prior year's results.
Average growth rate+219.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.